undamentalytics Newsletter
Sign in

Coya Therapeutics, Inc. (COYA) stock

Add to watchlist

Add holding +

NASDAQ: COYA Nasdaq Biotechnology Next results ~November 11, 2026

C+ Fundamentals grade

Coya Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Coya Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Coya Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds19 adding, 23 cuttingOf 8 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Coya Therapeutics files

Where Coya Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $8m, up 1793.8% on a year earlier, faster than the 115.4% growth a quarter earlier. That growth ranks 5 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -196.3% from -3896.6% a year earlier. Operating margin widened to -288.7% from -5342.3%. The diluted share count is up 22.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks.

Our model value for Coya Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Coya Therapeutics, Inc.'s trailing-twelve-month revenue grew 1793.8% year on year, with a free-cash-flow margin of -196.3%. Where it stands out: change in growth rate of +1678.3pp ranks 4 of 172 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 1793.8% (+1678.3pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 1793.8% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 1678.3 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 5053.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -288.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -196.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 66.3% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 22.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 60% and a beta of 1.7 against the S&P 500.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.28 against an average estimate of -$0.36: beat by 22.8%
Revenue
$0m, up 49.0% on a year earlier
Share reaction
+1.1% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.35

Coya Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.9%
  • 1 week-23.9%
  • 1 month-34.8%
  • This year-44.3%
  • 1 year-47.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$8M
Operating margin
-288.7%
Net margin
-270.2%
EPS (TTM, diluted)
$-1.09

Growth

Revenue growth
+1793.8%
Change in growth rate
+1678.3 pts
Share count change
+22.4%

Cash

Free cash flow (TTM)
-$15.7M
FCF margin
-196.3%
Stock pay % of revenue
66.3%

Earnings

Last results
August 11, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Coya Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Coya Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.4 ~$0.9–$3.1 Left out: out of range vs price (0.13x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Coya Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$4.74$7.41$5.73$5.80$3.23
Market value$49m$75m$87m$97m$64m
+ Net debt (− = net cash)$7m−$33m−$38m−$47m−$43m
Enterprise value$56m$43m$49m$50m$21m
Multiples
Price / sales —12.5x24.6x12.2x8.0x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open. Analysts expect revenue of $78570 and EPS of −$0.35 (range −$0.37 to −$0.33) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.37 −8% $1m −87%
Next −$1.92 −41% $5m +387%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −7.3% on 90 days ago. In the last 30 days, 2 analysts raised Coya Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Coya Therapeutics, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.48 Current fiscal year, 60 days ago: −$1.42 Current fiscal year, 30 days ago: −$1.37 Current fiscal year, 7 days ago: −$1.37 Current fiscal year, Now: −$1.37 −$1.37 Next fiscal year, 90 days ago: −$1.83 Next fiscal year, 60 days ago: −$1.73 Next fiscal year, 30 days ago: −$1.88 Next fiscal year, 7 days ago: −$1.88 Next fiscal year, Now: −$1.92 −$1.92

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.48−$1.83
60 days ago −$1.42−$1.73
30 days ago −$1.37−$1.88
7 days ago −$1.37−$1.88
Now −$1.37−$1.92

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.36 −$0.28 +22.8%
Mar 2026 −$0.39 −$0.32 +18.0%
Dec 2025 −$0.30 −$0.34 −14.3%
Sept 2025 −$0.30 −$0.13 +57.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 11, 2026

No numeric guidance in Coya Therapeutics, Inc.'s latest earnings release (filed August 11, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202677
  2. Sep 202677
  3. Aug 202677

Counts of recommendations published by analysts covering Coya Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.4%
of tradable shares
Days to cover
7.79
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
33%
of shares
Held by insiders
14.7%
of shares
Employees
8
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −48.9%

$6.32 on October 31, 2025 to $3.23

ThenNowEffect
Revenue (last 12 months) $423452 $8m +1793.8%
P/S multiple n/m 8.0x −96.7%
Share count 16m 20m −18.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 2023202420252026 to date
Return
COYA+56%−23%+1%−44%
Industry peers (median)−18%−29%−5%−26%
S&P 500+26%+25%+18%+11%
Months that ended higher
COYA42%42%67%55%
S&P 50067%75%75%46%
Largest fall from a high during the year
COYA−43%−53%−33%−47%
S&P 500−10%−8%−19%−9%

Worst fall since December 29, 2022: 68% from October 28, 2024 to November 2, 2026. Getting back needed a 216% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.23 – $6.51
From 52-week high
−50.4%
vs 50-day average
−29.5%
vs 200-day average
−30.4%
Volatility (1 year)
60%
Beta vs S&P 500
1.69

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±4.9%
After a week
4 up, 8 down
typical move ±5.9%
After a month
4 up, 8 down
typical move ±10.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +1.1% −0.1% +6.0% −2.6%
May 12, 2026 +8.6% +0.4% +9.3% +11.0%
March 16, 2026 −2.9% +1.3% −6.8% 0.0%
November 12, 2025 −0.8% −1.6% −3.7% +2.8%
August 12, 2025 +0.8% +1.4% −3.4% +1.0%
May 13, 2025 −7.3% +0.8% −4.6% −12.5%
March 18, 2025 −5.8% 0.0% −4.4% −23.8%
November 6, 2024 +7.1% +3.3% +7.4% −9.2%
August 12, 2024 −15.2% +1.7% −7.3% −1.7%
May 9, 2024 +2.2% +0.7% +5.9% −11.6%
March 19, 2024 +1.0% +1.5% −10.2% −14.4%
November 8, 2023 −5.6% −0.7% −1.7% +36.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Coya Therapeutics, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Coya Therapeutics, Inc.
$0 $5M $10M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY23 Q4: $6M Revenue (TTM), FY24 Q1: $6.1M Revenue (TTM), FY24 Q2: $9.6M Revenue (TTM), FY24 Q3: $9.6M Revenue (TTM), FY24 Q4: $3.6M Revenue (TTM), FY25 Q1: $3.7M Revenue (TTM), FY25 Q2: $423.5K Revenue (TTM), FY25 Q3: $4M Revenue (TTM), FY25 Q4: $7.9M Revenue (TTM), FY26 Q1: $7.9M Revenue (TTM), FY26 Q2: $8M $8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $6M
FY24 Q1 $6.1M
FY24 Q2 $9.6M
FY24 Q3 $9.6M
FY24 Q4 $3.6M
FY25 Q1 $3.7M
FY25 Q2 $423.5K
FY25 Q3 $4M
FY25 Q4 $7.9M
FY26 Q1 $7.9M
FY26 Q2 $8M
Revenue growth, TTM YoY Coya Therapeutics, Inc.
-500% 0% 500% 1000% 1500% 2000% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q4: -40.8% Revenue growth, TTM YoY, FY25 Q1: -39.9% Revenue growth, TTM YoY, FY25 Q2: -95.6% Revenue growth, TTM YoY, FY25 Q3: -58.3% Revenue growth, TTM YoY, FY25 Q4: 123.6% Revenue growth, TTM YoY, FY26 Q1: 115.4% Revenue growth, TTM YoY, FY26 Q2: 1793.8% 1793.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 -40.8%
FY25 Q1 -39.9%
FY25 Q2 -95.6%
FY25 Q3 -58.3%
FY25 Q4 123.6%
FY26 Q1 115.4%
FY26 Q2 1793.8%
Operating margin (TTM) Coya Therapeutics, Inc.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY23 Q4: -131.7% Operating margin (TTM), FY24 Q1: -171.1% Operating margin (TTM), FY24 Q2: -109.6% Operating margin (TTM), FY24 Q3: -118.8% Operating margin (TTM), FY24 Q4: -485.4% Operating margin (TTM), FY25 Q1: -527.6% Operating margin (TTM), FY25 Q2: -5342.3% Operating margin (TTM), FY25 Q3: -516.7% Operating margin (TTM), FY25 Q4: -283.9% Operating margin (TTM), FY26 Q1: -283.6% Operating margin (TTM), FY26 Q2: -288.7% -288.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -131.7%
FY24 Q1 -171.1%
FY24 Q2 -109.6%
FY24 Q3 -118.8%
FY24 Q4 -485.4%
FY25 Q1 -527.6%
FY25 Q2 -5342.3%
FY25 Q3 -516.7%
FY25 Q4 -283.9%
FY26 Q1 -283.6%
FY26 Q2 -288.7%
FCF margin (TTM) Coya Therapeutics, Inc.
-4000% -3000% -2000% -1000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY23 Q4: -186.9% FCF margin (TTM), FY24 Q1: -84.9% FCF margin (TTM), FY24 Q2: -72.2% FCF margin (TTM), FY24 Q3: -106.2% FCF margin (TTM), FY24 Q4: -290.3% FCF margin (TTM), FY25 Q1: -414.9% FCF margin (TTM), FY25 Q2: -3896.6% FCF margin (TTM), FY25 Q3: -305.2% FCF margin (TTM), FY25 Q4: -135.5% FCF margin (TTM), FY26 Q1: -178.1% FCF margin (TTM), FY26 Q2: -196.3% -196.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -186.9%
FY24 Q1 -84.9%
FY24 Q2 -72.2%
FY24 Q3 -106.2%
FY24 Q4 -290.3%
FY25 Q1 -414.9%
FY25 Q2 -3896.6%
FY25 Q3 -305.2%
FY25 Q4 -135.5%
FY26 Q1 -178.1%
FY26 Q2 -196.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 6 4 8 8
EBITDA −10 −8 −17 −23 −23
Operating income −10 −8 −17 −23 −23
Net income −12 −8 −15 −21 −22
Diluted EPS −$1.18 −$0.79 −$0.98 −$1.27 −$1.09
Growth (year on year)
Revenue — — −40.8% +123.6% +>999%
Margins
EBITDA margin — −131.2% −484.6% −283.5% −288.5%
Operating margin — −131.7% −485.4% −283.9% −288.7%
Net margin — −133.1% −418.7% −267.1% −270.2%
Cash flow
Cash from operations −7 −11 −10 −11 −16
Stock-based pay 0 1 3 4 5
Balance sheet
Cash 6 33 38 47 43
Total debt 13 — 0 0 0
Net debt (negative = net cash) 7 −33 −38 −47 −43
Diluted shares 10m 10m 15m 17m 20m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $47m
Short-term assets $47mLonger-term assets $0m
What it owes, and who funded it · $47m
Short-term liabilities $4mLonger-term liabilities $1mShareholders' equity $43m
  • Short-term assets cover short-term liabilities $47m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $47m short-term assets against $519,636 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Coya Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+22.4%
year over year
R&D spending
211.8%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated COYA ACRS ADAG APLM ROIV EVAX Median
Revenue, last 12 months $8m $8m $8m $9m $8m $8m $56m
Revenue growth, last 12 months >999% −51.0% >999% — −67.6% 125.1% 12.6%
Revenue growth, 3-year average — −35.9% — — −46.4% — 13.7%
Revenue growth, latest quarter 49.0% −8.3% — — −33.5% — 10.2%
Operating margin −288.7% <−999% −279.5% — <−999% −122.7% −189.4%
Operating margin, 3-year average <−999% −711.4% — — −102.3% — −363.5%
Net margin −270.2% −921.5% −229.6% −128.7% <−999% −102.4% −169.8%
Cash from operations / revenue −196.1% −755.1% −204.1% −122.0% <−999% −88.0% −168.0%
Free-cash-flow margin −196.3% −756.5% −204.3% −122.0% <−999% −88.2% −162.4%
Free-cash-flow margin, 3-year average <−999% −339.9% — — <−999% — −310.0%
Stock pay / revenue 66.3% 141.8% 48.8% −11.5% >999% 4.1% 20.0%
Change in share count 22.4% 25.5% 4.8% 41.8% 0.6% 497.3% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 1793.8% 12.6% 7 of 172
Change in growth rate Growth +1678.3pp -0.1pp 4 of 172
Operating margin Profitability -288.7% -189.4% 104 of 175
Net margin Profitability -270.2% -157.3% 107 of 180
Free-cash-flow margin Cash generation -196.3% -145.4% 99 of 176
Stock pay as % of revenue Cash generation 66.3% 19.2% 122 of 179
Change in share count Balance sheet 22.4% 7.9% 119 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$45.5M
Institutions reporting
54
Shares held vs prior quarter
▼ 4.1%
Positions opened / closed
5 / 7

Top buyers and sellers, Q2 2026: 19 institutions bought and 23 sold ; the biggest buyer was Renaissance Technologies LLC (+89K shares) and the biggest seller Aigh Capital Management LLC (−343K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Dme Capital Management, LP $13.7M 2.3M 30.1% 0.0%
Vanguard Capital Management LLC $4.9M 842K 10.8% ▼ 0.3%
Alyeska Investment Group, L.P. $4.7M 800K 10.3% 0.0%
Aigh Capital Management LLC $3.7M 632K 8.1% ▼ 35.2%
Cm Management, LLC $2.3M 400K 5.1% ▲ 6.7%
Private Management Group Inc $2.2M 384K 4.9% ▲ 4.1%
Marshall Wace, LLP $1.5M 250K 3.2% ▲ 10.6%
Geode Capital Management, LLC $1.3M 228K 2.9% ▼ 2.2%
Renaissance Technologies LLC $1.1M 193K 2.5% ▲ 85.6%
Prosight Management, LP $994,500 170K 2.2% ▼ 59.6%
Dimensional Fund Advisors LP $913,036 156K 2.0% ▲ 62.6%
Vanguard Fiduciary Trust Co $757,873 130K 1.7% ▼ 7.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Coya Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 16, 2026
  • November 12, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Coya Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Coya Therapeutics, Inc. in brief

What does Coya Therapeutics, Inc. do?
Coya Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Coya Therapeutics, Inc.'s stock ticker?
Coya Therapeutics, Inc. trades under the ticker COYA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Coya Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Coya Therapeutics, Inc. reported revenue of $8M, 1793.8% higher than a year earlier, according to its SEC filings.
What is Coya Therapeutics, Inc.'s free cash flow?
Coya Therapeutics, Inc.'s free-cash-flow margin is -196.3% of revenue over the trailing twelve months, ranking 99 of the 176 biotechnology companies we cover.
Who are Coya Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Dme Capital Management, LP, Vanguard Capital Management LLC and Alyeska Investment Group, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Coya Therapeutics, Inc.'s market cap?
On November 2, 2026, Coya Therapeutics, Inc.'s market capitalisation was about $64.3M and net debt of -$43.2M. Market figures come from third-party market data and may be delayed.
Who are Coya Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Coya Therapeutics, Inc. are Aclaris Therapeutics, Inc., Adagene Inc., Apollomics Inc., Roivant Sciences Ltd. and Evaxion A/s. The side-by-side comparison below sets their revenue, margins and growth against Coya Therapeutics, Inc.'s.
When is Coya Therapeutics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Coya Therapeutics, Inc. announces its own schedule.